Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107419 · ClinicalTrials.gov registry record · Phase 2
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
A Phase 2 study of Sarcoma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT00107419: Completed Phase 2 study of Sarcoma, sponsored by SWOG Cancer Research Network.
NCT00107419 is a Phase 2 study of Sarcoma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 75 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107419, a Phase 2 study of Sarcoma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent and unresectable or metastatic chondrosarcoma.
Primary Outcome
x-rays or scans
Conditions Studied
Interventions
- DRUG pemetrexed disodium
Study Locations (20)
Montana
- CCOP - Montana Cancer Consortium - Billings
- Hematology-Oncology Centers of the Northern Rockies - Billings - Billings
- Northern Rockies Radiation Oncology Center - Billings
- St. Vincent Healthcare - Billings
- Deaconess Billings Clinic - Downtown - Billings
- Bozeman Deaconess Hospital - Bozeman
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
- Carle Cancer Center at Carle Foundation Hospital - Urbana
- CCOP - Carle Cancer Center - Urbana
Missouri
- CCOP - Cancer Research for the Ozarks - Springfield
- St. John's Regional Health Center - Springfield
- Hulston Cancer Center at Cox Medical Center South - Springfield
Kansas
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center - Kansas City
- Tammy Walker Cancer Center at Salina Regional Health Center - Salina
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
Georgia
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center - Savannah
Indiana
- Saint Anthony Memorial Health Centers - Michigan City
Massachusetts
- Cancer Research Center at Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00107419 record still lists
NCT00107419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which pemetrexed disodium is the first listed.
NCT00107419 names 20 study sites across 8 states, led by Montana, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT00107419 about?
NCT00107419 is a clinical study titled "S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma". RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent and unresectable or metastatic chondrosarcoma.
What is the current status of trial NCT00107419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-09. Estimated completion is 2009-08.
What conditions does trial NCT00107419 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00107419?
The interventions under investigation include: pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00107419?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107419 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00107419's enrollment target sits among peer trials
75 51st of 122 higher than 72 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia